Skip to main content

Trikafta Side Effects

Generic name: elexacaftor / ivacaftor / tezacaftor

Medically reviewed by Drugs.com. Last updated on Nov 29, 2023.

Note: This document contains side effect information about elexacaftor / ivacaftor / tezacaftor. Some dosage forms listed on this page may not apply to the brand name Trikafta.

Applies to elexacaftor / ivacaftor / tezacaftor: oral granule, oral tablet.

Serious side effects of Trikafta

Along with its needed effects, elexacaftor/ivacaftor/tezacaftor may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking elexacaftor/ivacaftor/tezacaftor:

Incidence not known

Other side effects of Trikafta

Some side effects of elexacaftor / ivacaftor / tezacaftor may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to elexacaftor / ivacaftor / tezacaftor: oral granule, oral tablet.

General

The most commonly reported adverse reactions in 5% of patients or greater included headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, increased blood creatine phosphokinase, increased aspartate aminotransferase, rhinorrhea, rhinitis, influenza, sinusitis, and increased blood bilirubin. The safety profile was generally consistent among pediatric and adult patients.[Ref]

Cardiovascular

Common (1% to 10%): Elevated blood pressure

Dermatologic

Common (1% to 10%): Rash, acne, eczema, pruritus

Rash includes generalized rash, erythematous rash, macular rash, and pruritic rash.

Gastrointestinal

Very common (10% or more): Upper, lower, and general abdominal pain (up to 14%), diarrhea (up to 13%)

Common (1% to 10%): Flatulence, abdominal distension

Genitourinary

Common (1% to 10%): Dysmenorrhea, urinary tract infection

Hepatic

Very common (10% or more): Increased ALT (up to 10%)

Common (1% to 10%): Increased AST, increased bilirubin levels

Postmarketing report: Liver failure leading to transplantation, liver injury characterized by concomitant transaminase and total bilirubin elevations

Hypersensitivity

Postmarketing reports: Hypersensitivity reactions (angioedema and anaphylaxis)

Metabolic

Common (1% to 10%): Hypoglycemia

Musculoskeletal

Common (1% to 10%): Increased creatine phosphokinase

Nervous system

Very common (10% or more): Headache (17%)

Common (1% to 10%): Dizziness

Ocular

Elexacaftor / ivacaftor / tezacaftor:

-Common (1% to 10%): Conjunctivitis

Ivacaftor-Containing Regimens:

-Frequency not reported: Non-congenital lens opacities/cataracts (pediatric patients)

Other

Common (1% to 10%): Increased C-reactive protein, influenza, ear pain, ear discomfort, tinnitus, tympanic membrane hyperemia, vestibular disorder, breast mass

Uncommon (0.1% to 1%): Ear congestion, breast inflammation, gynecomastia, nipple disorder, nipple pain

Respiratory

Very common (10% or more): Infective pulmonary exacerbation of cystic fibrosis (up to 21.8%), sputum increased (up to 19.8%), cough (up to 16.8%), upper respiratory tract infection (up to 16%), bacteria in sputum (greater than 10%)

Common (1% to 10%): Nasal congestion, rhinorrhea, rhinitis, sinusitis, pharyngitis, respiratory tract infection, tonsillitis, hemoptysis, oropharyngeal pain, nasopharyngitis, pharyngeal erythema, abnormal breathing

Uncommon (0.1% to 1%): Wheezing

Frequently asked questions

References

1. Product Information. Trikafta (elexacaftor / ivacaftor / tezacaftor). Vertex Pharmaceuticals. 2019.

2. Product Information. Trikafta (elexacaftor / ivacaftor / tezacaftor). Vertex Pharmaceuticals. 2023.

3. Product Information. Trikafta (elexacaftor / ivacaftor / tezacaftor). Vertex Pharmaceuticals Australia Pty Ltd. 2024.

4. Product Information. Kaftrio (elexacaftor / ivacaftor / tezacaftor). Vertex Pharmaceuticals (Europe) Ltd. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.